Try our Advanced Search for more refined results

Expert Analysis

REMS Abuse And Antitrust Injury: Round Peg, Square Hole

Law360, New York (November 4, 2015, 12:55 PM EST) -- In recent years, a small crop of complaints have alleged that brand pharmaceutical companies take advantage of distribution restrictions in U.S. Food and Drug Administration-imposed "risk evaluation and mitigation strategy" — or REMS — programs to delay or block generic competition.[1] Recently, district courts issued motion to dismiss decisions in two such cases: Natco Pharma Ltd. v. Gilead Sciences Inc. and Express Scripts Holding Co.[2] and In re Thalomid and Revlimid Antitrust Litigation.[3]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!